ESR1 and breast cancer: More specifically, luminal breast cancer cells characterized by miR-221/222 overexpression are marked by greater aggressiveness (high Ki67 proliferation index and tumor grade) [74] and higher rates of acquired resistance to selective estrogen receptor downregulator (SERD) fulvestrant [73].